Seattle Genetics (SGEN) PT Lowered to $64 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
February 7, 2019 4:05 PM ESTSeattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.75), $0.32 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $174.51 million versus the consensus estimate of $163.71 million.
During 2018, we received FDA approval for two ADCETRIS frontline indications, a major accomplishment that significantly expands the number of patients eligible to benefit from... More
